Septerna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain.
Latest Septerna news
We have not published a story on Septerna yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $84.7 million, plus short-term investments of $287.7 million, $372.3 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Septerna
Has Septerna raised money recently?
Our latest story on this, dated Mar 10, 2026: "Septerna files automatic shelf with $150,000,000 ATM sales agreement prospectus". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Septerna?
Septerna, Inc. trades under the ticker SEPN on NASDAQ.
Where is Septerna listed?
Septerna, Inc. is listed on NASDAQ.
What is the SEC CIK of Septerna?
The SEC Central Index Key (CIK) for Septerna, Inc. is 1984086. Its filings are on SEC EDGAR.
How many shares does Septerna have outstanding?
46,676,947 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-10.
Which country or territory is Septerna listed under?
Our directory records Septerna, Inc. under United States.
What does Septerna do?
Our directory classifies Septerna, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Septerna?
The ISIN recorded for Septerna, Inc. is US81734D1046.
Does aibio.space cover Septerna?
aibio.space lists Septerna, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Septerna incorporated?
SEC records list its state or country of incorporation as DE.
What was Septerna's revenue last year?
$46.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Septerna profitable?
Septerna, Inc. reported a net loss of $48.9 million for the fiscal year ended Dec 31, 2025, and generated $110.2 million of cash from operations, per its annual report to the SEC.
How much does Septerna spend on research and development?
$97.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Septerna have?
$372.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Septerna (SEPN) stock news?
Our latest story on Septerna, dated Mar 10, 2026: "Septerna files automatic shelf with $150,000,000 ATM sales agreement prospectus". Septerna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain. Source.
Investor discussion: Septerna
Members talk about Septerna (SEPN). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Septerna, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SEPN on TradingView.
SEC filings and registration
SEC name
Septerna, Inc.
CIK
1984086
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
SEPN (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
Phone
650-338-3533
Shares outstanding
46,676,947 as of 2026-08-05 (10-Q filed 2026-08-10)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Septerna, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SEPN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio